Scholarlink

<p>Laryngopharyngeal reflux (LPR) is a common yet under diagnosed condition characterized by the backflow of gastric contents into the larynx and pharynx. While proton pump inhibitors (PPIs) are the mainstay of treatment, many patients remain symptomatic. Magnesium deficiency has been linked to esophageal dysmotility and reflux, but its role in LPR remains unexplored. To evaluate the efficacy of magnesium supplementation in improving symptoms and findings in LPR patients. A prospective study of 68 LPR patients was conducted. Patients were randomized into two groups: Group A (<i>n</i> = 34) received standard PPI therapy, and Group B (<i>n</i> = 34) received PPI plus magnesium oxide (400&#xa0;mg/day). Symptoms were assessed using the Reflux Symptom Index (RSI), and laryngoscopic findings were graded using greater reduction in symptoms (mean RSI decrease: 12.4 vs. 8.2, <i>p</i> = 0.003) and mucosal inflammation (mean RFS decrease: 6.1 vs. 4.3, <i>p</i> = 0.012). Magnesium supplementation may enhance the therapeutic response in LPR when combined with PPIs, possibly by improving esophageal motility and reducing reflux episodes. Further large-scale studies are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of Magnesium Supplementation in Laryngopharyngeal Reflux Disease: A Randomized Controlled Study

  • 期刊论文

  • 发表日期：

    2025年8月27日

查看全文
  • Neeti Sahay,
  • Alok Yadav,
  • Rashmi Goyal,
  • Simran Kaur,
  • Shubhangi Gupta,
  • Man Prakash Sharma

摘要

Laryngopharyngeal reflux (LPR) is a common yet under diagnosed condition characterized by the backflow of gastric contents into the larynx and pharynx. While proton pump inhibitors (PPIs) are the mainstay of treatment, many patients remain symptomatic. Magnesium deficiency has been linked to esophageal dysmotility and reflux, but its role in LPR remains unexplored. To evaluate the efficacy of magnesium supplementation in improving symptoms and findings in LPR patients. A prospective study of 68 LPR patients was conducted. Patients were randomized into two groups: Group A (n = 34) received standard PPI therapy, and Group B (n = 34) received PPI plus magnesium oxide (400 mg/day). Symptoms were assessed using the Reflux Symptom Index (RSI), and laryngoscopic findings were graded using greater reduction in symptoms (mean RSI decrease: 12.4 vs. 8.2, p = 0.003) and mucosal inflammation (mean RFS decrease: 6.1 vs. 4.3, p = 0.012). Magnesium supplementation may enhance the therapeutic response in LPR when combined with PPIs, possibly by improving esophageal motility and reducing reflux episodes. Further large-scale studies are warranted.